[(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone
C25H22ClN5O — CID 125023413
Data last refreshed: (MolForge compound catalog, from PubChem)
About [(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone
[(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone (PubChem CID 125023413) has the molecular formula C25H22ClN5O and a molecular weight of 443.94 g/mol. Its IUPAC name is [(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone.
Molecular Properties
| Compound Name | [(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone |
|---|---|
| PubChem CID | 125023413 |
| Molecular Formula | C25H22ClN5O |
| Molecular Weight | 443.94 g/mol |
| Exact Mass | 443.15 |
| IUPAC Name | [(2R)-2-[2-(3-chlorophenyl)pyrimidin-4-yl]pyrrolidin-1-yl]-[2-(imidazol-1-ylmethyl)phenyl]methanone |
| SMILES | O=C(c1ccccc1Cn1ccnc1)N1CCC[C@@H]1c1ccnc(-c2cccc(Cl)c2)n1 |
| InChI | InChI=1S/C25H22ClN5O/c26-20-7-3-6-18(15-20)24-28-11-10-22(29-24)23-9-4-13-31(23)25(32)21-8-2-1-5-19(21)16-30-14-12-27-17-30/h1-3,5-8,10-12,14-15,17,23H,4,9,13,16H2/t23-/m1/s1 |
| InChIKey | YYBKRACEQWLYOW-HSZRJFAPSA-N |
| XLogP | 5.02 |
| TPSA | 63.91 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 443.94 |
| LogP ≤ 5 | 5.02 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 125023413 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.